Donnchadh Ó Laoghaire (Cork South Central, Sinn Fein)
Link to this: Individually | In context | Oireachtas source

93. To ask the Minister for Health the orphan medicines and technologies that will be considered in relation to the working group to bring forward appropriate decision criteria for the reimbursement of orphan medicines and technologies; if there are medicines earmarked that need to be evaluated under any new criteria developed; if the decision criteria will be open and transparent; the persons or bodies involved in the decision making process; and if he will make a statement on the matter. [4557/17]

Marcella Corcoran Kennedy (Offaly, Fine Gael)
Link to this: Individually | In context | Oireachtas source

The HSE has advised my Department that the terms of reference for the proposed Rare Diseases Technology Review Group are being finalised. They will be discussed at an upcoming meeting of the HSE Optimising Pharmaceutical Value Group prior to being submitted to the National Drugs Management Programme Sponsorship Group for consideration.

The timeline for establishment of this group is subject to, among other things, approval of the National Drugs Management Programme Sponsorship. The Rare Disease drugs for consideration by the Rare Diseases Technology Review Group will be determined at a later stage in this process.